- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about LLY
Recent news which mentions LLY
From Benzinga
Eli Lilly Issues Cease-And-Desist Letters to Compounders Over Weight-Loss Drug Copies As Shortage Resolves
October 10, 2024
From Benzinga
2 No-Brainer Dividend Growth Stocks to Buy Right Now
October 10, 2024
From Motley Fool
Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients
October 09, 2024
From Benzinga
CVS, UnitedHealth Request FTC Chair Recusal Amid Ongoing Pharmacy Benefit Managers Lawsuit
October 09, 2024
From Benzinga
What's Going With WeightWatchers Stock On Wednesday?
October 09, 2024
From Benzinga
FDA Sparks Controversy With Sudden Removal Of Eli Lilly's Weight Loss Drug From Shortage List
October 08, 2024
From Benzinga
With Its GLP-1 Drugs No Longer in a Shortage, Is Now the Time to Buy Eli Lilly Stock?
October 08, 2024
From Motley Fool
Billion-Dollar News for Eli Lilly Stock Investors
October 07, 2024
From Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
October 07, 2024
From Benzinga
Regeneron Chief Flags Health Risks with Popular Weight-Loss Medications Like Ozempic, Says Company Targets Muscle Preservation For Its Obesity Drugs
October 07, 2024
From Benzinga
2 Next-Gen Weight Loss Stocks That Are Worth Buying Right Now
October 07, 2024
From Motley Fool
From Benzinga
From Motley Fool
Hims & Hers Health Asserts Demand For Its Compounded Weight Loss Offering To Continue Despite Resolved Supply Shortages
October 04, 2024
From Benzinga
Evaluating Eli Lilly Against Peers In Pharmaceuticals Industry
October 04, 2024
From Benzinga
England's NHS Proposes Phased Rollout of Eli Lilly's Mounjaro, Considers Digital Services to Boost Access
October 04, 2024
From Benzinga
Massive News for Hims & Hers Stock: The Truth About Today's Move
October 04, 2024
From Motley Fool
Texas Attorney General Sues Insulin Manufacturers and Pharmacy Benefit Managers Over Price-Fixing Conspiracy That Increased Prices by 1,000%
October 03, 2024
From Benzinga
Cracking The Code: Understanding Analyst Reviews For Eli Lilly
October 03, 2024
Tickers
LLY
From Benzinga
Popular Weight Loss Drugs Like Ozempic Show Gap Between Clinical Trial Promises And Real-World Use, Study Reveals
October 03, 2024
From Benzinga
Hims & Hers Health Stock Is Tumbling Thursday: Here's Why
October 03, 2024
From Benzinga
This IPO Biotech Stock Could Be the Next Eli Lilly
October 03, 2024
From Motley Fool
Tandem Diabetes Insulin Pump Demand to Surge Despite Popular Demand Of Weight Loss Drugs, Bullish Analyst Says
October 02, 2024
From Benzinga
Eli Lilly Commits $4.5B To New Facility, Banking On Mounjaro, Zepbound's Weight Loss Success Despite Short-Term Stock Challenges
October 02, 2024
From Benzinga
Eli Lilly Invests $4.5B In New Medicine Foundry for Advanced Drug Manufacturing To Push US Pharma Boundaries
October 02, 2024
From Benzinga
Eli Lilly Nears First Trillion Pharma Title, But Investors Caution Amid Sky-High Valuation
October 02, 2024
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.